Sex differences in heart failure mortality by ejection fraction subtype: a single-center, retrospective cohort study Authors: Abiden Kapar, Xingli Gu, Fengwei Liang, Xuanjie Hu, Dandan Tang Published: 2025 ABSTRACT BackgroundHeart failure (HF) is a complex clinical syndrome characterized by structural or functional impairments in ventricular filling or ejection, leading to significant morbidity and mortality. This study investigates sex-specific differences in mortality across HF subtypes: heart failure with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF).MethodsA single-center, retrospective cohort study was conducted at the First Affiliated Hospital of Xinjiang Medical University, China, from August 16, 2012, to January 1, 2025. Patients diagnosed with HF based on the 2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure were included. Data on demographics, clinical parameters, and HF subtypes were extracted. Cox proportional hazards regression models assessed all-cause mortality risk, with Kaplan–Meier analysis for survival curves.ResultsOf 12,282 HF patients screened, 6,091 were included (median age: 69 years, IQR: 60–78). Females were older (median age: 72 vs. 67 years, p < 0.001) and had higher left ventricular ejection fraction (LVEF) (50.47% ± 11.47% vs. 45.61% ± 10.83%, p < 0.001) than males. Hypertension was prevalent in 61.3% of patients. Cox regression identified age as an independent risk factor for all-cause mortality (aHR: 1.04, 95% CI: 1.01–1.06, p = 0.002). In the HFmrEF subgroup, female sex was an independent predictor of mortality (aHR: 4.75, 95% CI: 1.47–15.35, p = 0.009). Age also predicted mortality in HFpEF (aHR: 1.04, 95% CI: 1.00–1.07, p = 0.025). No significant sex-based differences were observed in overall mortality (p = 0.12).ConclusionsAge is a significant independent risk factor for all-cause mortality in HF patients, with female sex emerging as a critical predictor in the HFmrEF subtype. These findings highlight the need for sex-specific risk stratification and tailored management strategies, particularly for females with HFmrEF. Future prospective, multi-center studies are needed to validate these results and explore underlying mechanisms to optimize HF outcomes. Introduction Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection, driven by a variety of underlying etiologies. The cardinal manifestations of HF include dyspnea and fatigue—which may limit exercise tolerance—as well as fluid retention that can lead to pulmonary and systemic congestion and peripheral edema (1–3). The clinical syndrome of HF may result from disorders of the pericardium, myocardium, endocardium, heart valves, or great vessels or from certain metabolic abnormalities, but most patients with HF have symptoms due to impaired left ventricular (LV) myocardial function (4, 5). HF has become a growing public health challenge associated with substantial morbidity and mortality (6, 7), placing an unprecedented cost burden on healthcare systems worldwide. Despite widespread adoption of evidence-based pharmacological and device therapies, an unacceptably high number of patients continue to experience functional impairment, poor quality of life, and premature death due to HF (8, 9). According to the classifications by organizations such as the Heart Failure Society of America, the Heart Failure Association of the European Society of Cardiology, the Japanese Heart Failure Society, and the Writing Committee for the Universal Definition of Heart Failure, HF is categorized as follows: HF with reduced ejection fraction (HFrEF) (HF with LVEF ≤ 40%), HF with mildly reduced ejection fraction (HFmrEF) (HF with LVEF 41%–49%), and HF with preserved ejection fraction (HFpEF) (HF with LVEF ≥ 50%) (10–12). Notable sex differences exist in cardiac physiology and function, leading to distinct clinical presentations and outcomes (13–15). Typically, females develop HF later in life, primarily due to hypertension, obesity, or diabetes-related microvascular changes associated with HFpEF (14, 16), whereas males are more likely to experience HFrEF secondary to macrovascular ischemia (17). Beyond structural and etiological differences, hormonal variations influence ventricular remodeling in females, resulting in symptom profiles that differ from those in males (18). The purpose of this study is to compare differences between sexes and among various HF subtypes. Methods Study design and setting We conducted a single-center, retrospective cohort study at the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, China, from August 16, 2012, to January 1, 2025. The study enrolled hospitalized patients with HF, all of whom underwent echocardiography during their initial hospitalization. The diagnosis of HF was strictly based on the criteria outlined in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure (2018 edition). We included patients hospitalized for HF and extracted comprehensive data from the hospital medical information database. The collected data encompassed: (1) Demographic characteristics: sex, age, occupation, body mass index (BMI), and number of comorbidities; (2) Medical history: family history and cardiovascular family history; (3) Clinical parameters: vital signs, hypertension, coronary disease, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDD), echocardiographic findings, laboratory test results, length of hospitalization, in-hospital outcomes, mortality, and HF subtypes (reduced, mildly reduced, and preserved). Study participants and procedure Patients were categorized into three HF subtypes based on LVEF: HF with reduced ejection fraction: LVEF ≤ 40% (1, 10); HF with mildly reduced ejection fraction: 41% ≤ LVEF ≤ 49%; HF with preserved ejection fraction: LVEF ≥ 50%. Participant selection criteria The study enrolled adults aged 18 years or older who had been diagnosed with heart failure (HF) based on the criteria outlined in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure (2018) (19). Eligible participants were those classified as New York Heart Association (NYHA) functional class II to IV (20), reflecting moderate to severe heart failure symptoms. Additionally, all participants were required to have received heart failure-specific treatment during their hospitalization to ensure relevance to the study's focus on HF management. To maintain the study's focus and data integrity, individuals were excluded if their hospitalization was primarily for conditions unrelated to heart failure. Furthermore, participants were not included if critical data, such as left ventricular ejection fraction (LVEF) measurements or hospitalization duration records, were unavailable, as these were essential for the study's analyses. Those with a diagnosis of renal insufficiency were also excluded to avoid confounding factors related to kidney function. Lastly, individuals lacking essential baseline or follow-up information were not included to ensure comprehensive data for analysis. Outcome measures and covariates The primary outcome of this study was all-cause mortality. The primary analysis examined sex-based differences in all-cause mortality, while secondary outcomes assessed mortality differences among HF subtypes (HFrEF, HFmrEF, and HFpEF). Follow-up began at hospital admission and continued until outcome occurrence (in-hospital death). The analyzed covariates included: sex, occupation, BMI, number of comorbidities, hypertension, coronary disease, family history, cardiovascular family history, LVEF, LVDD, mortality and HF subtypes (reduced, mildly reduced, and preserved). Statistical analysis Continuous variables were presented as mean with interquartile range (IQR), while categorical variables were expressed as counts and percentages. Group comparisons for continuous variables were performed using Student's t-test, and chi-square tests were used for categorical variables, with a p-value < 0.05 considered statistically significant. Kaplan–Meier (K-M) analysis was employed to plot cumulative mortality curves for all-cause mortality, and Cox proportional hazards regression models were applied to estimate hazard ratios (HR) with corresponding 95% confidence intervals (95% CI). All data processing and statistical analyses were conducted using R statistical software (version 4.2.3), with the “survival” and “survminer” packages utilized for Cox regression modeling and K-M curve generation. Results A total of 12,282 HF patients were initially enrolled. After strict screening, 6,091 patients met the inclusion criteria (Figure 1). The overall population had a median age of 69 years (IQR: 60–78) and a median hospital stay of 6 days (IQR: 5–8). Hypertension was present in 61.3% of patients, and nearly half were retired. Compared to males, female patients were older (median age: 72 vs. 67 years, p < 0.001) and had a higher LVEF (50.47% ± 11.47% vs. 45.61% ± 10.83%, p < 0.001) (Table 1). All-cause mortality was numerically higher in females than in males (p = 0.12, Figure 2). A similar trend was observed in the HFrEF subtype (p = 0.92, Figure 3), whereas the opposite pattern was noted in the HFpEF subtype (p = 0.81, Figure 5). In terms of HF type distribution, the proportion of males was significantly higher than that of females in both HFrEF and HFmrEF (74.9% vs. 25.1% and 71.3% vs. 28.7%, respectively) (Table 2). Flowchart of samples selection. Cumulative incidence in male and female with heart failure patients. Cumulative incidence in male and female with heart failure reduced ejection fraction (HFrEF) patients. Table 1Sex differences in clinical and echocardiographic characteristics of heart failure patients.CharacteristicsAll patients N = 6,091Male N = 3,999Female N = 2,092 p Age, year, median (IQR)69.00 (60.00, 78.00)67.00 (58.00, 76.00)72.00 (63.00, 80.00)<0.001Occupation, n (%) Farmers1,348 (22.1)829 (20.7)519 (24.8)<0.001 Retirees2,975 (48.8)1,894 (47.4)1,081 (51.7) Other occupational groups1,768 (29.0)1,276 (31.9)492 (23.5)Body mass index group, n (%) Underweight: < 18.5 kg/m2161 (3.2)68 (2.0)93 (5.4)<0.001 Normal weight: 18.5–24.9 kg/m22,057 (40.5)1,287 (38.3)770 (44.6) Overweight: 25–30 kg/m21,957 (38.5)1,388 (41.3)569 (33.0) Obesity: > 30 kg/m2909 (17.9)615 (18.3)294 (17.0) BMI, kg/m2, median (IQR)25.71 (22.98, 28.72)25.95 (23.42, 28.73)24.99 (22.04, 28.52)<0.001Number of comorbidities, n (%) N = 12,125 (34.9)1,458 (36.5)667 (31.9)0.003 N = 21,693 (27.8)1,101 (27.5)592 (28.3) N = 31,045 (17.2)656 (16.4)389 (18.6) N = 4572 (9.4)377 (9.4)195 (9.3) N ≥ 5656 (10.8)407 (10.2)249 (11.9)Hypertension, n (%)3,736 (61.3)2,454 (61.4)1,282 (61.3)0.971Coronary, n (%)1,302 (21.4)928 (23.2)374 (17.9)<0.001Diabetes, n (%)1,933 (31.7)1,293 (32.3)640 (30.6)0.175Family history, n (%)1,599 (26.3)1,102 (27.6)497 (23.8)0.002Family history of cardiovascular disease, n (%)1,144 (18.8)777 (19.4)367 (17.5)0.079LVEF, (%), mean (SD)47.28 (11.29)45.61 (10.83)50.47 (11.47)<0.001LVDD, mm, mean (SD)58.18 (9.70)60.48 (9.46)53.77 (8.56)<0.001HFrEF, n (%)2,008 (33.0)1,504 (37.6)504 (24.1)<0.001HFmrEF, n (%)1,689 (27.7)1,205 (30.1)484 (23.1)HFpEF, n (%)2,394 (39.3)1,290 (32.3)1,104 (52.8)Death, n (%)114 (1.9)67 (1.7)47 (2.2)0.144 Sex differences in clinical and echocardiographic characteristics of heart failure patients. Table 2Clinical characteristics of the patients with heart failure with reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) left ventricular ejection fraction.CharacteristicsHFrEF N = 2,008HFmrEF N = 1,689HFpEF N = 2,394 P Age, year, median (IQR)65.00 (57.00, 73.00)68.00 (59.00, 77.00)73.00 (63.00, 82.00)<0.001Sex, n (%) Male1,504 (74.9)1,205 (71.3)1,290 (53.9)<0.001 Female504 (25.1)484 (28.7)1,104 (46.1)Occupation, n (%) Farmers513 (25.5)369 (21.8)466 (19.5)<0.001 Retirees815 (40.6)816 (48.3)1,344 (56.1) Other occupational groups680 (33.9)504 (29.8)584 (24.4)Body mass index group, n (%) Underweight: < 18.5 kg/m245 (2.6)34 (2.4)82 (4.3)0.002 Normal weight: 18.5–24.9 kg/m2690 (40.0)583 (40.6)784 (40.7) Overweight: 25–30 kg/m2670 (38.9)590 (41.1)697 (36.2) Obesity: > 30 kg/m2318 (18.5)229 (15.9)362 (18.8)BMI, kg/m2, median (IQR)25.78 (23.35, 28.73)25.70 (23.23, 28.65)25.69 (22.49, 28.89)0.213Number of comorbidities, n (%) N = 1818 (40.7)606 (35.9)701 (29.3)<0.001 N = 2589 (29.3)468 (27.7)636 (26.6) N = 3304 (15.1)312 (18.5)429 (17.9) N = 4152 (7.6)155 (9.2)265 (11.1) N ≥ 5145 (7.2)148 (8.8)363 (15.2)Hypertension, n (%)1,145 (57.0)1,055 (62.5)1,536 (64.2)<0.001Coronary, n (%)421 (21.0)386 (22.9)495 (20.7)0.213Diabetes, n (%)648 (32.3)550 (32.6)735 (30.7)0.371Family history, n (%)566 (28.2)450 (26.6)583 (24.4)0.014Family history of cardiovascular disease, n (%)435 (21.7)305 (18.1)404 (16.9)<0.001LVEF, (%), mean (SD)34.84 (4.42)44.68 (2.36)59.55 (4.34)<0.001LVDD, mm, mean (SD)66.49 (8.16)59.08 (6.06)50.58 (6.44)<0.001Death, n (%)27 (1.3)22 (1.3)65 (2.7)<0.001 Clinical characteristics of the patients with heart failure with reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) left ventricular ejection fraction. Clinical characteristics differed by sex across HF subtypes. Male HFrEF patients had a higher family history disease and larger LVDD. In HFmrEF, male patients had a higher prevalence of coronary disease and larger LVDD, but lower mortality during follow-up compared to females (p = 0.025, Figure 4). In HFpEF, male patients had higher rates of coronary disease, higher LVEF, and larger LVDD than females (Table 3). Cumulative incidence in male and female with heart failure mildly reduced ejection fraction (HFmrEF) patients. Cumulative incidence in male and female with heart failure preserved ejection fraction (HFpEF) patients. Table 3Clinical characteristics of sex with heart failure with reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) left ventricular ejection fraction.CharacteristicsHFrEF N = 2,008HFmrEF N = 1,689HFpEF N = 2,394Male N = 1,504Female N = 504Male N = 1,205Female N = 484Male N = 1,290Female N = 1,104Age, year, median (IQR)63.00 (55.00, 72.00)69.00 (60.00, 75.25)*67.00 (58.00, 76.00)71.00 (62.00, 78.25)*71.00 (62.00, 82.00)75.00 (66.00, 82.00)*Occupation, n (%) Farmers357 (23.7)156 (31.0)*241 (20.0)128 (26.4)*231 (17.9)235 (21.3)* Retirees609 (40.5)206 (40.9)*580 (48.1)236 (48.8)*705 (54.7)639 (57.9)* Other occupational groups538 (35.8)142 (28.2)*384 (31.9)120 (24.8)*354 (27.4)230 (20.8)*Body mass index group, n (%) Underweight: < 18.5 kg/m219 (1.5)26 (5.9)*22 (2.1)12 (3.0)*27 (2.6)55 (6.2)* Normal weight: 18.5–24.9 kg/m2487 (37.9)203 (46.2)*394 (38.2)189 (46.7)*406 (38.9)378 (42.9)* Overweight: 25–30 kg/m2529 (41.2)141 (32.1)*445 (43.2)145 (35.8)*414 (39.7)283 (32.1)* Obesity: > 30 kg/m2249 (19.4)69 (15.7)*170 (16.5)59 (14.6)*196 (18.8)166 (18.8)*BMI, kg/m2, median (IQR)26.12 (23.53, 29.03)24.80 (21.90, 27.73)*25.83 (23.44, 28.72)25.00 (22.66, 28.30)*25.95 (22.97, 28.73)25.25 (21.88, 28.91)*Number of comorbidities, n (%) N = 1622 (41.4)196 (38.9)444 (36.8)162 (33.5)392 (30.4)309 (28.0)* N = 2425 (28.3)164 (32.5)329 (27.3)139 (28.7)347 (26.9)289 (26.2)* N = 3233 (15.5)71 (14.1)223 (18.5)89 (18.4)200 (15.5)229 (20.7)* N = 4116 (7.7)36 (7.1)105 (8.7)50 (10.3)156 (12.1)109 (9.9)* N ≥ 5108 (7.2)37 (7.3)104 (8.6)44 (9.1)195 (15.1)168 (15.2)*Hypertension, n (%)874 (58.1)271 (53.8)748 (62.1)307 (63.4)832 (64.5)704 (63.8)Coronary, n (%)331 (22.0)90 (17.9)305 (25.3)81 (16.7)*292 (22.6)203 (18.4)*Diabetes, n (%)490 (32.6)158 (31.3)392 (32.5)158 (32.6)411 (31.9)324 (29.3)Family history, n (%)445 (29.6)121 (24.0)*332 (27.6)118 (24.4)325 (25.2)258 (23.4)Family history of cardiovascular disease, n (%)332 (22.1)103 (20.4)219 (18.2)86 (17.8)226 (17.5)178 (16.1)LVEF, (%), mean (SD)34.84 (4.40)34.83 (4.50)44.66 (2.34)44.73 (2.42)59.06 (4.37)60.12 (4.24)*LVDD, mm, mean (SD)67.51 (8.19)63.44 (7.24)*60.20 (6.10)56.29 (4.97)*52.56 (6.64)48.26 (5.33)*Death, n (%)20 (1.3)7 (1.4)11 (0.9)11 (2.3)*36 (2.8)29 (2.6)*p < 0.05: comparisons between male VS female in the same HF subtype. Clinical characteristics of sex with heart failure with reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) left ventricular ejection fraction. *p < 0.05: comparisons between male VS female in the same HF subtype. Cox regression analysis indicated that age was an independent risk factor for all-cause mortality (aHR: 1.04, 95% CI: 1.01–1.06, p = 0.002), with each additional year of age associated with a 4% increase in mortality risk. Additionally, patients with two comorbidities showed a trend toward higher all-cause mortality compared to those with only one comorbidity (aHR: 1.76, 95% CI: 1.00–3.11, p = 0.051) (Table 4). Table 4Cox regression analysis for all-cause mortality in heart failure patients.CharacteristicsSample sizeEvent (%)Univariable analysisMultivariable analysisHR (95% CI) P aHR (95% CI) p Age6,091114 (1.87%)1.06 (1.04–1.08)<0.0011.04 (1.01–1.06)0.002Sex, male3,99967 (1.68%)1.00 (Reference) Female2,09247 (2.25%)1.35 (0.93–1.96)0.1171.00 (0.62–1.62)0.994Occupation, farmers1,3489 (0.67%)1.00 (Reference) Retirees2,97578 (2.62%)1.80 (1.05–3.06)0.0311.64 (0.88–3.06)0.119 Other occupational groups1,76827 (1.53%)0.46 (0.32–0.65)<0.0010.76 (0.49–1.20)0.240Body mass index group, underweight1614 (2.48%)1.00 (Reference) Normal weight: 18.5–24.9 kg/m22,05742 (2.04%)0.55 (0.25–1.19)0.1270.95 (0.42–2.15)0.904 Overweight: 25–30 kg/m21,95724 (1.23%)1.10 (0.59–2.05)0.7701.09 (0.58–2.06)0.779 Obesity: >30 kg/m290911 (1.21%)1.20 (0.79–1.83)0.4001.20 (0.79–1.84)0.388Number of comorbidities, n = 12,12530 (1.41%)1.00 (Reference) N = 21,69326 (1.54%)2.34 (1.59–3.44)<0.0011.76 (1.00–3.11)0.051 N = 31,04516 (1.53%)1.58 (1.04–2.41)0.0311.49 (0.91–2.46)0.112 N = 457212 (2.10%)1.20 (0.75–1.90)0.4451.33 (0.72–2.46)0.370 N ≥ 565630 (4.57%)0.97 (0.60–1.57)0.9051.35 (0.76–2.41)0.307Hypertension3,73676 (2.03%)1.26 (0.85–1.86)0.2410.96 (0.59–1.56)0.856Coronary1,30221 (1.61%)0.83 (0.52–1.33)0.4370.70 (0.40–1.22)0.204Diabetes1,93344 (2.28%)1.36 (0.93–1.98)0.1111.03 (0.63–1.69)0.895Family history1,59929 (1.81%)0.96 (0.63–1.46)0.8371.05 (0.45–2.46)0.905Family history of cardiovascular disease1,14422 (1.92%)1.03 (0.65–1.65)0.8881.21 (0.47–3.14)0.697LVEF6,091114 (1.87%)1.03 (1.01–1.04)0.0010.98 (0.93–1.05)0.623LVDD6,091114 (1.87%)0.97 (0.95–0.99)0.0041.01 (0.97–1.05)0.695LVEF, HFrEF2,00827 (1.34%)1.00 (Reference)HFmrEF1,68922 (1.30%)1.65 (1.20–2.27)0.0021.66 (0.59–4.70)0.337HFpEF2,39465 (2.72%)1.37 (0.93–2.02)0.1111.45 (0.90–2.35)0.131 Cox regression analysis for all-cause mortality in heart failure patients. Subgroup analysis further revealed that among HFmrEF patients, female was an independent risk factor for all-cause mortality (aHR: 4.75, 95% CI: 1.47–15.35, p = 0.009). In HFpEF patients, age remained an independent predictor of mortality (aHR: 1.04, 95% CI: 1.00–1.07, p = 0.025) (Table 5). Table 5Cox regression analysis for all-cause mortality by heart failure with reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) left ventricular ejection fraction.CharacteristicsSample sizeEvent (%)Univariable analysisMultivariable analysisHR (95% CI) P aHR (95% CI) p HFrEF N = 2,008Age2,00827 (1.34%)1.04 (1.00–0.07)0.0281.02 (0.98–1.07)0.332Sex, male1,50420 (1.33%)1.00 (Reference) Female5047 (1.39%)1.05 (0.44–2.48)0.9160.55 (0.17–1.77)0.315Occupation, farmers5132 (0.39%)1.00 (Reference) Retirees81517 (2.09%)2.19 (0.73–6.55)0.1611.69 (0.53–5.45)0.376 Other occupational groups6808 (1.18%)0.40 (0.19–0.83)0.0150.51 (0.21–1.25)0.141Body mass index group, underweight452 (4.44%)1.00 (Reference) Normal weight: 18.5–24.9 kg/m26909 (1.30%)0.39 (0.12–1.24)0.1110.42 (0.11–1.62)0.210 Overweight: 25–30 kg/m26706 (0.90%)2.21 (0.82–5.98)0.1172.58 (0.91–7.27)0.074 Obesity: >30 kg/m23184 (1.26%)0.97 (0.44–2.13)0.9350.97 (0.43–2.16)0.933Number of comorbidities, n = 181812 (1.47%)1.00 (Reference) N = 25896 (1.02%)1.62 (0.67–3.88)0.2832.23 (0.69–7.25)0.182 N = 33043 (0.99%)1.96 (0.75–5.11)0.1662.14 (0.73–6.26)0.165 N = 41522 (1.32%)1.04 (0.35–3.04)0.9461.30 (0.30–5.61)0.721 N ≥ 51454 (2.76%)1.02 (0.33–3.13)0.9751.74 (0.45–6.69)0.420Hypertension1,14514 (1.22%)0.81 (0.38–1.72)0.5810.58 (0.23–1.46)0.244Coronary4213 (0.71%)0.47 (0.14–1.56)0.2180.31 (0.08–1.21)0.091Diabetes64811 (1.70%)1.45 (0.67–3.12)0.3431.32 (0.51–3.46)0.568Family history5668 (1.41%)1.07 (0.47–2.45)0.8691.63 (0.35–7.61)0.537Family history of cardiovascular disease4356 (1.38%)1.03 (0.42–2.56)0.9411.02 (0.20–5.23)0.980LVEF2,00827 (1.34%)0.91 (0.85–0.98)0.0150.93 (0.84–1.03)0.151LVDD2,00827 (1.34%)1.03 (0.99–1.07)0.2011.02 (0.96–1.08)0.489HFmrEF N = 1,689Age1,68922 (1.30%)1.07 (1.03–1.11)0.0011.05 (0.99–1.12)0.106Sex, male1,20511 (0.91%)1.00 (Reference) Female48411 (2.27%)2.51 (1.09–5.80)0.0304.75 (1.47–15.35)0.009Occupation, farmers3692 (0.54%)1.00 (Reference) Retirees81616 (1.96%)1.31 (0.39–4.35)0.6581.55 (0.30–7.94)0.601 Other occupational groups5044 (0.79%)0.41 (0.18–0.95)0.0280.80 (0.26–2.46)0.694Body mass index group, underweight340 (0.00%)0 (not estimated)0 (not estimated) Normal weight: 18.5–24.9 kg/m25838 (1.37%)0 (not estimated)0 (not estimated) Overweight: 25–30 kg/m25907 (1.19%)0 (not estimated)0 (not estimated) Obesity: > 30 kg/m22290 (0.00%)0 (not estimated)0 (not estimated)Number of comorbidities, n = 16064 (0.66%)1.00 (Reference) N = 24689 (1.92%)2.00 (0.69–5.76)0.1990 (not estimated) N = 33123 (0.96%)1.49 (0.51–4.38)0.4700 (not estimated) N = 41551 (0.65%)3.38 (0.86–13.30)0.0820 (not estimated) N ≥ 51485 (3.38%)0.97 (0.27–3.50)0.9580 (not estimated)Hypertension1,05515 (1.42%)1.29 (0.52–3.16)0.5800.55 (0.18–1.70)0.298Coronary3866 (1.55%)1.26 (0.49–3.23)0.6241.12 (0.31–3.99)0.863Diabetes55010 (1.82%)1.74 (0.75–4.02)0.1982.86 (0.93–8.80)0.067Family history4507 (1.56%)1.28 (0.52–3.15)0.5840.07 (0.00–8.41)0.275Family history of cardiovascular disease3057 (2.30%)2.13 (0.87–5.21)0.09920.09 (0.16–2,556.38)0.225LVEF1,68922 (1.30%)0.92 (0.77–1.10)0.3590.98 (0.77–1.26)0.896LVDD1,68922 (1.30%)1.00 (0.94–1.08)0.8511.07 (0.97–1.19)0.170HFpEF N = 2,394Age2,39465 (2.72%)1.06 (1.03–1.08)<0.0011.04 (1.00–1.07)0.025Sex, male1,29036 (2.79%)1.00 (Reference) Female1,10429 (2.63%)0.94 (0.58–1.53)0.8090.67 (0.36–1.26)0.217Occupation, farmers4665 (1.07%)1.00 (Reference) Retirees1,34445 (3.35%)1.85 (0.91–3.79)0.0911.49 (0.65–3.42)0.348 Other occupational groups58415 (2.57%)0.56 (0.35–0.90)0.0170.95 (0.53–1.72)0.872Body mass index group, underweight822 (2.44%)1.00 (Reference) Normal weight: 18.5–24.9 kg/m278425 (3.19%)0.73 (0.25–2.11)0.5591.35 (0.44–4.13)0.598 Overweight: 25–30 kg/m269711 (1.58%)0.97 (0.41–2.29)0.9390.95 (0.40–2.29)0.915 Obesity: > 30 kg/m23627 (1.93%)1.53 (0.84–2.76)0.1611.50 (0.83–2.73)0.179Number of comorbidities, n = 170114 (2.00%)1.00 (Reference) N = 263611 (1.58%)2.45 (1.47–4.08)<0.0011.66 (0.80–3.45)0.173 N = 342910 (2.33%)1.47 (0.85–2.54)0.1631.41 (0.74–2.68)0.297 N = 42659 (3.40%)0.92 (0.50–1.67)0.7790.92 (0.43–2.00)0.839 N ≥ 536321 (5.79%)1.06 (0.57–1.96)0.8611.41 (0.68–2.94)0.357Hypertension1,53647 (3.06%)1.47 (0.85–2.53)0.1671.48 (0.73–3.02)0.277Coronary49512 (2.42%)0.87 (0.46–1.62)0.6530.77 (0.37–1.59)0.486Diabetes73523 (3.13%)1.24 (0.75–2.06)0.4050.64 (0.31–1.31)0.220Family history58314 (2.40%)0.85 (0.47–1.53)0.5891.17 (0.41–3.35)0.770Family history of cardiovascular disease4049 (2.23%)0.79 (0.39–1.59)0.5060.78 (0.22–2.81)0.701LVEF2,39465 (2.72%)1.05 (0.99–1.11)0.1081.02 (0.94–1.10)0.711LVDD2,39465 (2.72%)0.96 (0.92–1.00)0.0500.96 (0.91–1.03)0.238 Cox regression analysis for all-cause mortality by heart failure with reduced (HFrEF), mildly reduced (HFmrEF), and preserved (HFpEF) left ventricular ejection fraction. Discussion This study identifies a critical sex-specific disparity in HF outcomes, with female sex emerging as an independent predictor of increased mortality risk in the HFmrEF subgroup. This finding, derived from a single-center retrospective cohort study at Xinjiang Medical University First Affiliated Hospital, underscores the importance of sex as a key prognostic factor in HFmrEF, a subtype that bridges HFrEF and HFpEF. By highlighting this novel association, our work challenges the assumption that sex differences in HF outcomes are consistent across all subtypes and provides a clear direction for re-evaluating clinical and research approaches to HFmrEF. The elevated mortality risk in females with HFmrEF is a significant finding, as HFmrEF remains less well-characterized than HFrEF or HFpEF. Unlike HFrEF, which is more common in males and often linked to macrovascular ischemia, or HFpEF, which is frequently associated with hypertension and microvascular dysfunction in females, HFmrEF represents a heterogeneous group with unique pathophysiological features (17, 21). It is increasingly recognized that this heterogeneity encompasses patients recovering from prior HFrEF, those transitioning toward HFpEF, and individuals with acute decompensation (1, 11). This pathophysiological diversity likely underlies the variable treatment responses and prognostic patterns observed in HFmrEF, and may be a key factor contributing to the distinct sex-specific outcomes we identified in our cohort. Our results suggest that females with HFmrEF may face worse outcomes due to factors such as older age at diagnosis, distinct comorbidity profiles, or sex-specific hormonal influences on ventricular remodeling. This observation aligns with prior studies noting that females tend to develop HF later in life, often with clinical presentations driven by microvascular or metabolic stressors (22). However, our study extends these insights by pinpointing the prognostic significance of female specifically in HFmrEF, a subgroup often overlooked in large-scale cohort studies that dichotomize HF into HFrEF and HFpEF (23). The clinical implications of this finding are profound. The higher mortality risk in females with HFmrEF necessitates sex-specific risk stratification in clinical practice. Contemporary guidelines, including the 2022 AHA/ACC/HFSA and 2023 ESC focused update, have begun to recommend differential application of therapies across HF subtypes (1, 24). However, the evidence base for treating HFmrEF remains less robust than for other subtypes, and current recommendations provide little guidance on sex-specific management. Our results advocate for tailored approaches for females with HFmrEF (25, 26). Clinicians may need to prioritize aggressive management of comorbidities, such as hypertension or diabetes, which are more prevalent in females and may exacerbate HFmrEF outcomes (22, 27). Furthermore, the elevated risk in this subgroup calls for enhanced monitoring, potentially incorporating advanced imaging to detect subtle ventricular dysfunction or targeted therapies addressing sex-specific pathophysiological mechanisms. For example, exploring interventions that modulate hormonal influences on myocardial function could improve outcomes in females with HFmrEF (28, 29). Our findings challenge existing assumptions about sex differences in HF. Previous studies, such as Mansur et al. (30), reported no significant sex-based differences in overall HF mortality, with females exhibiting higher LVEF and smaller LVDD compared to males. In contrast, our study highlights a specific vulnerability in females with HFmrEF, suggesting that the intermediate ejection fraction range may confer unique risks not captured in studies focusing solely on HFrEF or HFpEF (23). Additionally, our results diverge from large prospective cohort studies that reported higher lifetime HF risk in males across all ages, potentially due to their exclusion of the HFmrEF category (31). This discrepancy underscores the importance of recognizing HFmrEF as a distinct entity in HF research and clinical guidelines (32, 33). The role of sex hormones in HF outcomes also warrants further exploration. While age-related declines in estrogen and testosterone are known to modulate ventricular myocyte mechanics, their impact on HFmrEF remains underexplored (34). Experimental evidence suggests that ovarian hormone deficiency may impair cardiomyocyte contractility, an effect potentially reversible with estrogen replacement therapy (28). In contrast, testosterone deficiency in males may contribute to contractile dysfunction in HFrEF but appears less relevant in HFmrEF (35). These findings suggest that hormonal therapies could be a promising avenue for future research, particularly for females with HFmrEF, to mitigate their elevated mortality risk. For future research, our study highlights the need for prospective studies to validate the sex-specific mortality risk in HFmrEF and investigate underlying mechanisms, such as microvascular dysfunction, inflammation, or genetic factors (36). Including HFmrEF as a distinct category in large-scale studies is critical, as its omission in prior research may have obscured important sex-based differences (17). Additionally, incorporating detailed medication and procedural data in future analyses could clarify how treatment variations influence outcomes in females with HFmrEF. Our findings also inspire research into novel therapeutic strategies, such as hormone modulation or personalized treatment plans, to address sex-specific risks in HF. This study has several limitations. As a single-center retrospective cohort study, the findings may be subject to selection bias and unmeasured confounders, potentially limiting generalizability. The absence of detailed medication and surgical intervention data may have influenced outcome assessments, as treatment differences could affect mortality risk. Additionally, the use of all-cause mortality as a composite endpoint, encompassing both cardiac and non-cardiac deaths, may introduce interpretation challenges. Despite these limitations, our study provides a compelling case for prioritizing sex-specific approaches in HFmrEF, with the potential to transform clinical practice and improve outcomes for a vulnerable population. Conclusion This study establishes female sex as an independent predictor of mortality in HFmrEF, offering a novel perspective on sex differences in HF outcomes. By emphasizing the unique prognostic significance of sex in this understudied subtype, our findings advocate for sex-specific risk stratification, tailored therapeutic strategies, and targeted research to address the elevated mortality risk in females with HFmrEF. These insights have the potential to reshape clinical practice and guide future investigations to optimize HF management across sexes and subtypes.